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Engineered ionizable lipid nanoparticles for targeted 
delivery of RNA therapeutics into different types of cells 
in the liver
M. Kim1, M. Jeong1, S. Hur2, Y. Cho2, J. Park3, H. Jung1, Y. Seo1, H. A. Woo1,  
K. T. Nam2, K. Lee1,4, H. Lee1*
Ionizable lipid nanoparticles (LNPs) have been widely used for in vivo delivery of RNA therapeutics into the liver. 
However, a main challenge remains to develop LNP formulations for selective delivery of RNA into certain types 
of liver cells, such as hepatocytes and liver sinusoidal endothelial cells (LSECs). Here, we report the engineered 
LNPs for the targeted delivery of RNA into hepatocytes and LSECs. The effects of particle size and polyethylene 
glycol–lipid content in the LNPs were evaluated for the hepatocyte-specific delivery of mRNA by ApoE-mediated 
cellular uptake through low-density lipoprotein receptors. Targeted delivery of RNA to LSECs was further investi-
gated using active ligands. Incorporation of mannose allowed the selective delivery of RNA to LSECs, while mini-
mizing the unwanted cellular uptake by hepatocytes. These results demonstrate that engineered LNPs have great 
potential for the cell type–specific delivery of RNA into the liver and other tissues.
INTRODUCTION
In recent years, RNA therapeutics have received tremendous atten-
tion as a tool to regulate gene expression in patients. These approaches 
include the regulation of abnormal gene expression by short inter-
fering RNA (siRNA) and mRNA (1–8). There have been two U.S. Food 
and Drug Administration–approved siRNA therapeutics (patisiran 
and givosiran) for rare disease treatments. These drugs target the 
selective degradation of mRNA to reduce the expression of disease- 
associated proteins in polyneuropathy and acute hepatic porphyria 
(2, 5, 9). In addition, synthetic mRNA can produce insufficient pro-
teins (e.g., factor IX and vascular endothelial growth factor) in pa-
tients to treat various diseases such as hemophilia A and ischemic 
heart disease (3, 6). Furthermore, in vivo genome editing has been 
introduced, and multiple studies reported a successful gene editing 
in mice by the delivery of a single guide RNA with synthetic mRNA 
encoding CRISPR-Cas9 (10, 11).
To fully realize the potential of RNA therapeutics, an efficient 
in vivo delivery system is of the utmost importance. Ionizable lipid 
nanoparticles (LNPs) have been widely used for the systemic delivery 
of RNA therapeutics. LNPs are mainly composed of ionizable lipid 
or lipid-like materials with helper lipid, cholesterol, and polyethylene 
glycol (PEG)–lipid. Previously, various types of ionizable lipid 
materials were reported for LNP formulations such as C12-200, 
cKK-E12, and DLin-MC3-DMA (12–14). These LNPs showed an 
efficient gene silencing in the liver at the dosing level of 0.002 mg of 
siRNA/kg (14). The mechanism of cellular uptake was well investigat-
ed, and adsorption of serum ApoE (apolipoprotein E) on the surface of 
LNPs was a major effector facilitating the intracellular delivery of LNPs 
into hepatocytes through low-density lipoprotein (LDL) receptors (15). 
Although LNPs are particularly advantageous for in vivo delivery, 
systemic delivery of RNA therapeutics other than liver hepatocytes 
remains highly challenging.
The liver consists of two major types of cells, including parenchymal 
cells (e.g., hepatocytes) and nonparenchymal cells [e.g., liver sinu-
soidal endothelial cells (LSECs), Kupffer cells, and stellate cells] (16–19). 
Given their physiological differences, a cell type–specific delivery of 
RNA in the liver requires a precise engineering of LNPs. For example, 
LSECs have the highest endocytic capacity without a basement mem-
brane, making them the most permeable among liver cells (20). 
LSECs have many fenestrae, allowing the facile transport of macro-
molecules between sinusoidal lumen and hepatocytes. Because of the 
average diameter of liver fenestrae (~100 nm in human and ~140 nm 
in mouse), only small nanoparticles can penetrate through these 
holes (21). Chen and coworkers (22) previously reported the effect 
of particle size on the in vivo potency of LNPs in the liver. They 
showed that the particle size heavily influenced the gene delivery 
efficacy of LNPs, as well as the stability of LNPs during blood 
circulation.
Nanoparticles that cannot penetrate through the fenestrae are 
taken up by different types of liver cells such as LSECs and Kupffer 
cells. It was shown that LNPs with larger particle size can be delivered 
to LSECs and induced Tie2 gene silencing (23). The size and com-
position of LNPs can help the endothelium-specific delivery; 
however, the detailed mechanism of cell-specific uptake is not well 
understood. Therefore, targeting specific cells in the liver requires 
an alternative strategy other than adjusting the physical size and 
composition of the LNPs. Ligand incorporation can be an ideal ap-
proach for selective delivery of RNA therapeutics to targeted liver 
cells. LSECs play an important role in scavenger system and ex-
press selective receptors such as stabilin receptors, mannose recep-
tors, and Fc-RIIb2 (17). These receptors are involved in the removal 
of blood-borne antigens by active endocytosis. For example, 
phosphorothioate-modified antisense oligonucleotides or hyaluronic 
acid–conjugated nanoparticles were successfully delivered to LSECs 
by targeting the scavenger receptors (24, 25).
In this study, we report the engineered LNP formulations for the 
targeted delivery of RNA into different types of cells in the liver. 
Hepatocytes and LSECs are two major cells involved in various 
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liver-related diseases. Hepatocytes are often associated with rare 
diseases in metabolism and endocrine dysfunctions, while LSECs 
are closely related with chronic liver diseases such as liver fibrosis 
and cirrhosis (19, 26, 27). It is important to selectively target the 
liver cells in different diseases, and its selectivity becomes more critical 
when introducing in vivo gene regulation and editing. Here, ioniz-
able lipids were first synthesized and screened for their pKa (where 
Ka is the acid dissociation constant) and endolytic activities. Select-
ed lipid candidates were further evaluated for in vitro and in vivo 
gene expression after formulating LNPs with reporter mRNA [fire-
fly luciferase (FLuc)]. Targeted delivery of LNPs with mRNA (Cre) 
in different types of cells in the liver was examined by controlling 
the particle size and PEG-lipid content of LNPs. In addition, engi-
neered LNPs with mannose moieties were prepared for active 
targeting of LSECs. Optimized condition for the targeted delivery 
of mRNA to LSECs was lastly confirmed. Additional in vivo gene 
silencing study revealed that these engineered LNPs provided com-
patible formulation parameters with siRNA. Moreover, the engineered 
LNPs with mannose moieties showed more selectivity over conven-
tional LNPs and provided superior potential for active targeting of 
LSECs in the liver.
RESULTS
Formulation of LNPs
To identify efficient ionizable lipid materials, we synthesized six dif-
ferent ionizable lipids by an epoxide ring-opening reaction with 
amines (Fig. 1, A and B). Previously, we reported poly(amido- 
amines), cystamine-bisacrylamide–106 (here reported as 246), for 
plasmid DNA transfection (28). This allowed enhanced transfection 
efficiency than a commercial agent in vitro. On the basis of previous 
study, we chose six different piperazine- or piperidine-containing 
amine candidates for this study. These amines were reacted under 
90°C, together with epoxide that has 10 carbon tails. Before testing 
pKa and transfection efficiency, resulting ionizable lipids were 
formulated into LNPs. As in previously reported studies, newly synthe-
sized ionizable lipids (241C10 to 246C10) were formulated into LNPs 
with dioleoylphosphatidylethanolamine (DOPE), cholesterol, and 
C16-PEG2000 ceramide (PEG-lipid) as well as mRNA by using a 
microfluidic-based system (29, 30). As a representative, 246C10 LNPs 
were imaged with cryo–transmission electron microscopy, and these 
LNPs had an average diameter of 60 to 100 nm (Fig. 1C).
Physicochemical properties of ionizable LNP candidates
Next, we evaluated the pKa of LNPs. LNPs were prepared with mRNA 
formulations. pKa of each LNPs was determined by 2-(p-toluidino)- 
6-napthalene sulfonic acid (TNS) assay (31–33). Formulated LNPs 
were titrated from pH range of 2.5 to 11.0 in 0.5 pH increments. The 
measured fluorescence was normalized by (fluorescence − minimum 
fluorescence) divided by the (maximum fluorescence − minimum 
fluorescence). The normalized fluorescence was evaluated by a curve 
fit analysis, and a fluorescence titration S curve was generated (fig. 
S3, A and B). From the resulting curves, pKa of LNPs was calculated 
(pH at 50% of maximum fluorescence) (fig. S3C). Anionic TNS 
interacts with positively charged ionizable lipids and becomes lipo-
philic. As the pH value approaches the pKa value of the each LNPs, 
TNS becomes less lipophilic and more water molecules can quench 
TNS fluorescence. Therefore, “S”-shaped curve with pKa of 6.5 to 
7.0 represents that these LNPs have a good chance to interact well 
with endosomal membrane and escape endosomes upon acidifica-
tion. Among ionizable lipid candidates, 244C10, 245C10, and 246C10 
resulted in a sharp sigmoidal-shaped curve with corresponding pKa 
values of 5.5, 5.6, and 6.75, respectively.
Characterization and evaluation of ionizable LNP 
candidates in vitro
To evaluate the efficacy of ionizable lipid candidates to deliver RNA 
in cells, we formulated six different LNPs with mRNA encoding 
Fig. 1. Preparation of LNPs derived from developed ionizable lipids. (A) Six different piperidine- and piperazine-containing amines used in this study. (B) Ionizable 
lipids were synthesized by epoxide ring opening with amines and epoxide containing 10 carbon tails. (C) LNPs were prepared via a microfluidic system with ionizable 
lipids, helper lipid, cholesterol, and PEG-lipid. Prepared LNPs were examined with cryo–transmission electron microscopy for their size and structural analysis.
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firefly luciferase (mFLuc). Before cellular transfection using HeLa 
cells, formulated LNPs (241C10 to 246C10) were incubated with 
apolipoprotein E3 (apoE3) at the concentration of 0.1 g/ml for 
10 min at room temperature. apoE3 is a major isoform of ApoE in 
human (34). As shown in fig. S4 (A to D), ApoE adsorption resulted 
in the increase in size of LNPs, confirmed by dynamic light scatter-
ing (DLS) measurement. It is well known that lipoproteins are asso-
ciated with LNPs in blood and enhance the cellular uptake of LNPs 
via LDL receptors (LDLRs). HeLa cells are known to express LDLR 
on their surface (15). Six hours after LNP treatments, cells were 
lysed with Bright-Glo reagent and the relative intensity of luciferase 
expression was evaluated. As shown in Fig. 2A, 244C10, 245C10, 
and 246C10 showed substanial luciferase expression and 246C10 
LNPs showed the highest luminescent expression. In serum-containing 
media, the role of ApoE was not significant (Fig. 2B), whereas in 
serum-free media, ApoE incubation resulted in the increase in 
luciferase expression (Fig. 2C). Although preincubation of 244C10 and 
245C10 LNPs with ApoE slightly enhanced the FLuc expression 
(100-fold), preincubation of 246C10 LNPs with ApoE showed the 
marked increase in FLuc expression by 400-fold. To further investi-
gate the cellular uptake mechanism of LNPs, intracellular uptake of 
LNPs was inhibited with anti-LDLR antibody (Fig. 2D). The signif-
icant inhibition was observed only with 246C10 LNP formulation. 
These findings suggested that cellular uptake of 246C10 LNPs was 
mainly mediated by interaction between ApoE and LDLR.
In vivo evaluation of ionizable LNP candidates 
for biodistribution and gene regulation
In addition to the in vitro evaluation of ionizable lipid candidates, 
we evaluated ionizable lipid candidates in vivo. LNPs with high 
transfection ability in previous data were pooled and formulated 
with mFLuc to confirm their biodistribution and FLuc expression. 
Sizes of mFLuc-loaded 244C10, 245C10, 246C10 LNPs were validated 
before injection. The mean particle size of LNPs remained relatively 
similar (60 to 70 nm). Formulated LNPs were intravenously injected 
to C57BL/6 mice. Luminescence was evaluated 3 hours after injec-
tion via live-animal and ex vivo organ imaging. As shown in Fig. 3, 
244C10, 245C10, and 246C10 LNPs mediated the liver-specific 
delivery and expression of mFLuc. Like the in vitro cellular study, 
246C10 LNPs showed the highest luciferase expression in the liver. 
In addition, ex vivo imaging of five different organs (liver, kidney, 
lung, spleen, and heart) supported the liver tissue–specific expres-
sion of mFLuc using 246C10 LNPs.
To figure out the impact of ApoE on the cellular uptake 
of 246C10 LNPs in vivo, we also evaluated luciferase expression in 
ApoE knockout mice (fig. S5, A to D). By injecting ApoE-associated 
246C10 LNPs in the ApoE knockout mice, luciferase expres-
sion was substantially increased in the liver. The result was 
consistent with in  vitro cellular uptake results and demonstrated 
that ApoE association could facilitate the delivery of 246C10 LNPs 
to the liver.
Fig. 2. In vitro evaluation of ionizable lipid candidates. Ionizable lipid candidates were formulated into LNPs with mFLuc, and their efficacy was evaluated in vitro. 
After incubation with ApoE, LNPs were treated to HeLa cells (96 wells) at mRNA dose of 100 ng (n = 4). (A) Expression of mFLuc after transfection of HeLa cells in the pres-
ence of serum and (B) in the presence or absence of ApoE. (C) ApoE rescues the transfection efficiency of 246C10 in the absence of serum. (D) Pretreatment of anti-LDLR 
antibody (Ab) to HeLa cells decreased luciferase expression in 246C10 LNP–treated HeLa cells. P > 0.05, ***P < 0.001 as compared with antibody-pretreated cells. FBS, fetal 
bovine serum.
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Next, we investigated the biodistribution of mRNA-loaded LNPs. 
Given the fact that injected LNPs (<100 nm) were mostly distributed 
to the liver, the question was which types of liver cells mostly uptake 
these LNPs. Previously, Chen et al. (22) reported on the size-dependent 
gene silencing of LNPs in hepatocytes, following intravenous injection. 
Upon entering systemic circulation, LNPs (<100 nm) were mostly 
accumulated in the liver. In particular, LNPs with sizes of 45 to 80 nm 
showed significant silencing in hepatocytes. To figure out which 
types of liver cells were mostly interacting with the formulated LNPs, 
we prepared Cre mRNA (mCre)–loaded LNPs with their size under 
100 nm. mCre was formulated into LNPs, and mCre dose of 0.5 mg/kg 
was injected into mice carrying a loxP-flanked stop cassette. Once a stop 
cassette is deleted, mice can express robust tdTomato fluorescence. 
Therefore, delivery of functional mCre allows the facile identification 
of cells transfected with formulated LNPs. As shown in Fig. 4A, robust 
tdTomato fluorescence was detected exclusively in the liver. To further 
confirm the cell type–specific gene edition in the liver, we extracted a 
mouse liver 2 days after injection and evaluated tdTomato fluorescence 
by the histology observation of liver tissue. Compared to phosphate- 
buffered saline (PBS)–injected mice, strong tdTomato fluorescence 
was detected in hepatocytes (Fig. 4B). To further examine transfec-
tion efficiency in different types of liver cells, we labeled hepatocytes, 
LSECs, and Kupffer cells with specific antibodies. Then, tdTomato 
fluorescence–positive cells were evaluated by histological analysis using 
the MetaMorph image software. As shown in Fig. 4C, 80% of hepato-
cytes, 40% of endothelial cells, and 10% of Kupffer cells exhibited 
the positive results of tdTomato fluorescence. In addition to the his-
tological evaluation, tdTomato fluorescence–positive cells were also 
confirmed by flow cytometry analysis (fig. S9B). Transfection efficiency 
in hepatocytes was the highest among different types of liver cells.
Targeted delivery of mRNA-loaded LNPs to different types 
of liver cells by controlling their size and PEG-lipid content
After establishing LNP delivery to hepatocytes, we examined the 
targeted delivery of mRNA-loaded LNPs to different types of liver 
cells by controlling their size and PEG-lipid content. Among these 
cells, we focused on LSECs, where many of liver-related diseases 
originated. First, we hypothesized that as LSECs reside in the liver 
blood wall, LNPs that cannot penetrate the fenestrae will be uptaken 
into the LSECs. We prepared various LNPs loaded with mCre, and 
their size was ranging from 50 to 100 nm by varying PEG-lipid (%) 
(Fig. 5, A and B). For a change in the mole ratio of PEG-lipid, the 
change must be replaced with the mole ratio of other components. 
Mole ratio of PEG-lipid was varied by expending that of cholesterol. 
We have chosen cholesterol because, first, cholesterol has the least 
effect on endosomal release compared to other lipids (35). Second, 
cholesterol accounts for a large mole ratio among the lipid compo-
sitions, so this small change only accounts for less than 10% of the 
original, which will have very little impact. LNPs with mCre (0.5 mg/kg) 
were intravenously injected into mice. Two-days after injection, the 
liver was extracted and tdTomato-positive cells were confirmed by 
histology evaluation and flow cytometry analysis.
Figure 5C and fig. S9 (A to C) show that LNPs with 68 nm 
(1.5% PEG-lipid) exhibited potent tdTomato fluorescence in hepato-
cytes. Smaller LNPs with less than 100 nm in size could easily pene-
trate the fenestrae upon entering the liver blood vessel and showed 
maximum expression of tdTomato fluorescence in hepatocytes at 
PEG-lipid content of 1.5% with 60 nm in size. However, reduced 
tdTomato fluorescence throughout the liver cells was observed with 
LNP formulations with 3% PEG-lipid. The observed phenome-
non of reduced tdTomato fluorescence in higher PEG-lipid content 
may be attributed to the reduced ApoE-mediated cellular uptake of 
LNPs (36). PEG-lipid content strongly affects the ApoE adsorption 
on the LNPs, and it was confirmed by ApoE enzyme-linked immuno-
sorbent assay (ELISA) (fig. S6). LNPs with 1.0, 1.5, 3.0, and 5.0% 
PEG-lipid were prepared. Prepared LNPs were incubated with ApoE 
and purified by ultracentrifugation. We then evaluated the amount 
of adsorbed ApoE by ELISA. Assuming that protein adsorption is 
governed by the surface area of LNP, ApoE adsorption per LNP 
particle was decreased when PEG-lipid was higher than 3%. This 
Fig. 3. In vivo evaluation of ionizable lipid candidates (mFLuc). Ionizable lipid candidates were formulated with mFLuc. mFLuc-loaded LNPs were injected to C57BL/6 
mice at mRNA dose of 0.1 mg/kg. Three hours after injection, bioluminescence was analyzed. 244C10- to 246C10-formulated LNPs resulted in potent luciferase expression. 
Ex vivo organ image showed that LNPs were mostly uptaken into liver. p, photons; PDI, polydispersity index.
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indicated that higher PEG content hindered the ApoE adsorption, 
thus resulting in the decrease of luciferase expression in mFLuc-loaded 
LNP–injected mice (fig. S7).
Potent tdTomato fluorescence in LSECs was observed for LNPs 
with 100 nm in size (1.0% PEG-lipid) that is similar to the diameter 
of fenestrae. However, the uptake of LNPs by LSECs was decreased 
correspondingly with the reduction in LNP size (60 nm). It is likely 
that more LNPs are directed to hepatocytes through fenestrae rath-
er than interacting with LSECs for cellular entry. Again, with higher 
PEG-lipid content of 3% or more, a poor ApoE association would 
be the cause of reduced tdTomato fluorescence. These results con-
firmed the importance of size and PEG-lipid content of LNPs 
governing their delivery efficacy to hepatocytes and LSECs. 
Unfortunately, LNPs with 1.0% PEG-lipid content not only showed 
increased LNP delivery into LSECs but also resulted in potent cellu-
lar uptake by hepatocytes. It would be difficult to achieve LSEC- 
specific delivery of RNA by controlling size and PEG-lipid content 
of LNPs. Therefore, a different strategy was needed.
Active targeting of LSECs using ligand-incorporated LNPs
Upon entering the blood stream, nanoparticles rapidly absorb se-
rum proteins on their surface. The effects of protein corona heavily 
control the biodistribution of nanoparticles. For some LNPs, ApoE 
adsorption is essential for the cellular uptake of LNPs. Akinc et al. 
(15) have described the role of ApoE in the in vivo uptake of LNPs 
by hepatocytes. They compared the uptake of LNPs by hepatocytes 
in wild-type and ApoE knockout mice. The activity of LNPs was 
remarkably reduced in ApoE knockout (ApoE−/−) mice compared 
to wild-type mice. Since the major cell population in the liver is he-
patocytes and they overexpress LDLR, an alternative targeting 
ligand is necessary for LSEC-specific delivery of RNA other than 
the ApoE. Previously, specific targeting ligands were evaluated for 
enhancing the selective delivery of LNPs to target cells (15). Kumar et al. 
(36) showed decreased activity of LNPs with higher PEG-lipid con-
tent in hepatocytes due to reduced association of ApoE with LNPs. 
They showed that LNPs with 5% PEG-lipid have a lower binding 
affinity with ApoE compared to LNPs with 1.5% PEG-lipid. By 
introducing unique targeting ligands to the highly PEGylated LNPs, 
ApoE-mediated cellular uptake can be blocked and selective deliv-
ery of LNPs can be achieved.
Among various liver cells, LSECs are substantial targets for RNA 
therapeutics because LSECs are closely related to fetal liver diseases 
resulting from LSECs-derived gene products (17, 19). To achieve 
the selective delivery of LNPs to LSECs, we introduced LSEC-specific 
ligands to highly PEGylated LNPs. Mannose receptor is one of 
the receptors that specifically expressed on human and mice LSECs 
(17). Mannose-conjugated nanoparticles have been investigated in 
various targeted delivery studies, and these nanoparticles have been 
proven to be safe (37, 38). To introduce mannose moieties on the 
surface of LNPs, we used mannose-PEG lipid (Fig. 6A). Since man-
nose is conjugated to PEG, when mannose-PEG lipid is formulated 
into LNPs together with other lipid components, mannose can be 
exposed to the outer layer of LNPs. First, we formulated LNPs with 
mannose-PEG lipid with different content and tested whether in-
troduction of mannose-PEG lipid can alter the cellular uptake of 
LNPs as compared to that of original LNPs in the absence of ApoE.
Mannose-PEG lipid was incorporated from 0.5 to 4.5% to LNPs 
with total 1.5, 3.0, and 5.0% PEG-lipid (Fig.  6B). Prepared LNPs 
with mFLuc were treated to the HepG2 cells with serum-containing 
media or serum-free media. Luciferase level was evaluated after 
24 hours. Since HepG2 cells are known to express mannose recep-
tor (CD206), mannose-mediated cellular uptake can be quantitatively 
evaluated (39, 40). Figure 6C shows that the uptake of mannose- 
incorporated LNPs into HepG2 cells via CD206 was enhanced with 
Fig. 4. In vivo evaluation of ionizable lipid candidates (mCre). Ionizable lipid candidates were formulated with mCre. mCre-loaded LNPs were injected to LSL-tdTomato 
at mRNA dose of 0.5 mg/kg. Two-days after injection, tdTomato fluorescence was analyzed. (A) Ex vivo organ image showed that LNPs were mostly uptaken into the liver. 
(B) Liver histology image showed significant tdTomato fluorescence in the hepatocyte. cv, central vein. (C) Transfection efficiency in hepatocytes, LSECs, and Kupffer cells 
was confirmed by histological analysis (n = 5). DAPI, 4,6-diamidino-2-phenylindole.
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increasing the content of mannose-PEG lipid in LNPs. Incorpora-
tion of mannose increased LNP uptake into HepG2 in the pres-
ence or absence of serum. To further evaluate the role of mannose 
incorporation in the uptake of LNPs by HepG2 cells, the mRNA 
expression level of mannose-incorporated LNPs was divided by 
that of LNPs with PEG-lipid only (Fig. 6D). Unexpectedly, incorpo-
ration of mannose to LNPs with 3.0% PEG-lipid showed a similar 
increase in mRNA expression level in the presence or absence of 
serum. On the contrary, for 1.5% PEG-lipid, incorporation of 
mannose did not result in an increase in mRNA expression level in 
the presence of serum compared to that in the absence of serum. In 
the presence of serum, uptake of mannose-incorporated LNPs with 
1.5% of PEG-lipid could be simultaneously internalized by ApoE- and 
mannose-mediated pathway. Therefore, mannose/CD206-mediated 
LNP uptake was less significant. However, higher PEG-lipid con-
tent (3%) could allow reduced absorption of ApoE and mediate 
LNP uptake mainly by mannose and CD206 interaction. To further 
figure out whether LNPs with mannose were internalized via 
CD206-mediated pathway, we performed a cellular uptake inhibi-
tion experiment (Fig. 6, E and F). Anti- CD206 antibody was pre-
treated to the cells, and LNPs with mannose-PEG lipid or 
galactose-PEG lipid were incubated with HepG2 cells. Galactose is 
the one of mannose enantiomers and adopted as a control. The sig-
nificant decrease in luciferase expression was confirmed when 
LNPs were incorporated with mannose- PEG. In contrast, mRNA 
expression of LNPs with galactose moieties was not inhibited by 
anti-LDLR antibody. This result indicated that mannose moieties 
could play an important role in CD206-mediated intracellular up-
take of LNPs.
Next, to evaluate the selective targeting of mannose-incorporated 
LNPs to LSECs, we performed in vivo evaluation with two different 
mRNAs (mFLuc and mCre). LNPs were formulated with 3.0% 
PEG-lipid (with 2.5% mannose-PEG lipid). Since extrahepatic macro-
phages also express CD206, we first confirmed the liver-specific 
delivery of mFLuc-loaded LNPs with mannose. In addition, we 
compared a ligand-dependent mRNA delivery efficiency of LNPs 
using mannose-PEG lipid with that of galactose-PEG lipid. As 
shown in fig. S8, LNPs with mannose-PEG lipid and galactose-PEG 
lipid resulted in slightly bigger size than LNPs with PEG-lipid only. 
This phenomenon was previously reported among saccharide- 
conjugated nanoparticles (41, 42). The prepared mFLuc-loaded LNPs 
were injected intravenously into C57BL/6 mice at a dose of 0.1 mg/kg. 
Fig. 5. In vivo delivery of mRNA-loaded LNPs to different types of liver cells by controlling their size and PEG-lipid content. (A) Formulation ratio between lipid 
components. PEG-lipid was changed from 1.0 to 3.0% by expending that of cholesterol. (B) Resulting size and encapsulation efficiency of mRNA-loaded LNPs with differ-
ent PEG-lipid density. (C) LSL-tdTomato mice were injected intravenously with mCre (0.5 mg/kg). After 2 days of injection, tdTomato fluorescence–positive liver cells were 
confirmed by histological analysis (n = 5).
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Whole-body image showed substantial bioluminescence in the mice 
liver with mannose-incorporated LNPs and supported the liver 
tissue–specific expression of mFLuc.
We then examined the ability of LSEC-specific gene editing 
using mCre. mCre-loaded LNPs with mannose were injected to mice 
at a dose of mRNA at 0.5 mg/kg. As shown in Fig. 7A, ex vivo organ 
images also confirmed robust liver-specific tdTomato fluorescence. 
Next, cell type–specific fluorescence was quantified by imaging tissue 
sections. Notable tdTomato fluorescence was detected along the 
liver vessel (LSECs), and Kupffer cells rarely expressed tdTomato 
fluorescence (Fig. 7B). We further quantified this phenomenon by 
counting tdTomato fluorescence–positive cells with MetaMorph 
image software. As shown in Fig. 7C, 15% of hepatocytes, 70% of 
LSECs, and 15% of Kupffer cells were tdTomato fluorescence posi-
tive. tdTomato fluorescence–positive cells were also confirmed by 
flow cytometry analysis (fig. S9D). Notably, compared with LNPs with 
3.0% PEG-lipid, mannose-incorporated LNPs showed the substan-
tial decrease of tdTomato fluorescence in hepatocytes. While some 
discussion exists about the expression of CD206 on the surface of 
mice Kupffer cells, in our data, incorporation of mannose seemed to 
Fig. 6. In vitro evaluation of receptor-mediated cellular uptake of mannose-LNPs. (A) Structure of mannose-PEG lipid. (B) Formulation details. (C) HepG2 cells were 
incubated with LNPs at 25 ng of mFLuc (n = 4). Mannose-lipid–incorporated LNPs allowed enhanced cellular internalization compared to LNPs with PEG-lipid only. 
(D) Relative FLuc expression of mannose-incorporated LNPs with respect to that of LNPs with PEG-lipid only. RLU, relative luminescence units; RFU, relative fluorescence 
units. Pretreatment of anti-CD206 resulted in decreased mRNA expression in LNPs with mannose-PEG lipid–treated HepG2 cells (E) but not in LNPs with PEG-galactose–
treated HepG2 cells (F). ns, not significant: P > 0.05; **P < 0.01 and ****P < 0.0001 as compared with LNPs formulated with PEG-lipid only.
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have little effect on the uptake of the LNPs by the Kupffer cells. These 
results demonstrated a highly effective targeting strategy to LSECs 
using mannose-incorporated LNPs.
Next, we confirmed the selective targeting of siRNA-loaded LNPs 
with mannose to LSECs. LNPs were formulated with 1.5% PEG-lipid 
(with 1.0% mannose-PEG lipid) and 3.0% PEG-lipid (with 2.5% 
mannose- PEG lipid) for targeting LSECs and compared the FVIII gene 
silencing efficiency to that of LNPs with PEG-lipid only. As shown 
in Fig. 8 (A and C), similar to that of mRNA-loaded LNPs, LNPs 
with mannose-PEG lipid resulted in slightly bigger size than LNPs 
with PEG-lipid only. The prepared LNPs with siFVIII were injected 
into C57BL/6 mice at the dose of 0.5 mg/kg. After 2 days of injec-
tion, blood was collected and the level of FVIII protein in serum was 
validated. As shown in Fig. 8B, addition of mannose-PEG lipid into 
LNPs with 3% total PEG-lipid content showed a more enhanced 
FVIII inhibition in LSECs. On the contrary, for 1.5% PEG-lipid, in-
corporation of mannose to LNPs was less significant. This could be 
due to high ApoE adsorption at lower PEG content that facilitated 
the ApoE/LDLR-mediated uptake of LNPs. In addition, we further 
compared the LNP uptake using mannose-PEG lipid with that of 
galactose-PEG lipid. As expected, galactose-incorporated LNPs showed 
similar diameter of mannose-incorporated LNPs. However, in vivo 
study revealed that significant FVIII inhibition was only observed 
in mannose-incorporated LNPs. To determine whether addition of 
mannose-PEG lipid could decrease the LNP uptake into hepato-
cytes, LNPs were formulated with siFVII and injected into C57BL/6 
mice at the dose of 0.2 mg/kg. As shown in Fig.  8D, addition of 
mannose-PEG lipid reduced the uptake of LNPs with 1.5 and 
3.0% PEG-lipid, whereas addition of galactose-PEG lipid was less 
significant.
DISCUSSION
A platform technology that delivers RNA therapeutics to targeted 
cells has great potential for treating various liver diseases associat-
ed with different types of cells in the liver. In particular, LSECs 
participate in initiation and progression of chronic liver diseases 
by change in their pathological characteristics in response to 
chemical toxins, cytokines, and inflammatory stimuli (17, 19). 
Previous studies have shown that targeting endothelial sphingosine- 
1-phosphate receptor-1 and Bax in LSECs could also reduce 
apoptosis of LSECs and eventually reduced acute hepatic failure 
(43, 44). The conjugation of hyaluronan, KLGR peptide, and 
mannose resulted in increased uptake of nano particles into LSECs 
Fig. 7. Targeted in vivo genome editing in LSECs by mannose-LNPs (mCre). Ionizable lipid candidates were formulated with mCre. mCre-loaded LNPs were injected 
to LSL-tdTomato mice at mRNA dose of 0.5 mg/kg. After 2 days of injection, tdTomato fluorescence was analyzed. (A) Ex vivo organ image showed that LNPs with man-
nose were mostly uptaken into the liver. (B) Liver histology image showed significant tdTomato fluorescence along the liver vessel. -SMA, –smooth muscle actin. 
(C) Transfection efficiency of mannose-LNPs was evaluated among hepatocytes, LSECs, and Kupffer cells by histological analysis (n = 5).
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compared to nonconjugated groups. Moreover, previously re-
ported studies have confirmed that LNPs can be delivered to 
different tissue by changing LNP formulations. Some of these for-
mulations showed increased mRNA delivery to LSECs without 
targeting ligands (45). Nevertheless, its selectivity remained not 
well understood (37).
To translate the targeted delivery to LSECs, ApoE-dependent 
cellular uptake must be replaced by alternative ligand selection and 
incorporation. Upon entering blood circulation system, LNPs can 
be readily delivered to hepatocytes and LSECs by ApoE-dependent 
cellular uptake. However, delivery efficacy of LNPs in LSECs is sig-
nificantly less than that of hepatocytes (23). Here, we demonstrated 
a targeted delivery of RNA to LSECs by incorporating active 
ligands to LNPs. The mannose ligand can interact with specific 
receptors (CD206) expressed on LSECs. We have shown that 
incorporation of mannose to LNPs with high PEG-lipid content 
(3%) allowed selective delivery of mRNA/siRNA only to LSECs 
through mannose-CD206 interaction. It is likely that, when PEG- 
lipid content is high enough, the ApoE-mediated cellular uptake is 
mostly reduced, while mannose-CD206 interaction becomes pre-
dominant for the cellular entry of LNPs. Moreover, mannose- 
incorporated LNPs showed bigger physical size than the diameter 
of the fenestrae. This additionally reduced the uptake of LNPs to 
hepatocytes and allowed more selective uptake into the LSECs. 
Collectively, our results successfully demonstrated the targeted 
delivery of RNA into different types of cells in the liver by con-
trolling physical size of LNPs, PEG-lipid content, and incorpora-
tion of active targeting ligands. Overall, this approach may offer 
new strategies to develop cell type–specific delivery of RNA in the 
liver and other tissues.
MATERIALS AND METHODS
Materials
241 to 244 and 246 amines were purchased from Sigma-Aldrich, and 
245 amine was purchased from Tokyo Chemical Industry (TCI). 
1,2-Distearoyl-sn-glycero- 3-phosphocholine (DSPC), 1,2-dioleoyl-sn-
glycero- 3-phosphoethanolamine (DOPE), and C16-PEG ceramide 
(PEG-lipid) were purchased from Avanti Polar Lipids. Cholesterol was 
purchased from Sigma-Aldrich. DSPE-PEG-mannose and DSPE-PEG- 
galactose were purchased from Biochempeg. Firefly luciferase mRNA 
(mFLuc) and mCre were purchased from TriLink BioTechnologies. 
d-luciferin and Bright-Glo reagent were purchased from Promega.
Preparation of ionizable lipids
Ionizable lipids were synthesized by epoxide ring-opening reaction. 
Reaction was conducted under solvent-free environment. To a solu-
tion of epoxide with 10 carbon tails (C10) (1,2-epoxydodecane; 
Sigma-Aldrich), piperazine- and piperidine-containing amines were 
added at a ratio of 1.2*N:1 epoxide/amine, where N is the number of 
secondary amine*1 + number of primary amine*2. For example, 
to synthesize 246C10, to a 5-ml vial, 1 ml of epoxide (4.65 mmol, 
4.8 equivalents) was added and 200 l of amine (0.97 mmol, 1 equiva-
lent) was added dropwise. The reaction solution was stirred at 300 rpm 
for 3 days at 90°C. Ionizable lipids were isolated as light yellow oil in 
70% yield using flash column chromatography system (CombiFlash). 
Representative nuclear magnetic resonance data and tandem mass 
spectrometry spectra for 246C10 are shown in figs. S1 and S2.
Preparation of ionizable LNPs
Ionizable LNPs were prepared as previously described (29, 30). Briefly, 
lipid components and RNAs were first dissolved in organic phase and 
Fig. 8. Selective in vivo gene silencing in LSECs using mannose-LNPs. C57BL/6 mice were injected with siFVII (0.2 mg/kg) or siFVIII (0.5 mg/kg; n = 3 to 5). (A and 
C) Formulation details. (B) Incorporation of mannose to LNPs with 3.0% of PEG-lipid increased the delivery of siRNA to LSECs but incorporation of galactose did not. 
(D) Incorporation of mannose to LNPs with 1.5 and 3.0% PEG-lipid reduced the delivery of siRNA to hepatocytes, whereas incorporation of galactose to LNPs with 3.0% 
PEG-lipid did not. (****P < 0.0001 as compared between sugar moiety–incorporated LNPs and LNPs with PEG-lipid only; ns: P > 0.05).
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aqueous phase to achieve a 1:3 volume ratio. For siRNA delivery, ioniz-
able lipids, cholesterol, DSPC, and PEG-lipid were dissolved in ethanol. 
siRNA was diluted in 50 mM sodium acetate. The final ionizable lipids: 
siRNA weight ratio was 7.5:1. For mRNA delivery, ionizable lipids, cho-
lesterol, DOPE, and PEG-lipid were dissolved in ethanol, and mRNA 
was diluted in 10 mM citrate. The final ionizable lipids:mRNA weight 
ratio was 10:1. Prepared solutions were mixed via a microfluidic mixing 
device at a flow rate of 12 ml/min to obtain LNPs. Then, prepared LNPs 
were dialyzed against PBS using 3500 MWCO (Molecular weight cut-
off) dialysis cassettes (Life Technologies) overnight. LNPs were charac-
terized for their size and RNA therapeutics encapsulation efficiency.
For confirming characterization of LNPs, LNPs were dialyzed to 
RNA dose of 0.001 mg/ml with PBS. DLS was used to confirm mean 
particle diameter, polydispersity index, and zeta potential. RNA 
therapeutics encapsulation efficiency was confirmed by RiboGreen 
Assay (Life Technologies) (29, 30).
TNS assay
pKa of formulated LNPs was evaluated by TNS assay as described 
previously (31–33). Briefly, pH buffers from 2.5 to 11.0 in 0.5 incre-
ments were prepared by adjusting a solution of 20 mM sodium 
phosphate, 25 mM citrate, 20 mM ammonium acetate, and 150 mM 
NaCl with 0.1 N NaOH and 0.1 N HCl. Each pH buffer was added 
to a black 96-well plate in 100 l. In addition, 300 M stock solution 
of TNS was added to the above pH buffer in the final concentration 
of 6 M. Last, formulated LNPs were added to the mixture solution 
in the final concentration of 25 M. Fluorescence intensity was 
obtained by Tecan at an excitation of 325 nm and an emission of 
435 nm. The measured fluorescence was normalized by (fluorescence − 
minimum fluorescence) divided by the (maximum fluorescence − 
minimum fluorescence). The normalized fluorescence was evaluated 
by a curve fit analysis, resulting in a fluorescence titration S curve. 
pKa of each LNPs was calculated as the pH value where half of the 
maximum fluorescence is reached.
In vitro evaluation of ionizable lipid candidates
HeLa cells were prepared in a white 96-well plate 16 hours before 
transfection at 80% confluency. Ionizable lipid candidates were for-
mulated into LNPs with mFLuc, together with DOPE, cholesterol, 
and PEG-lipid by pipetting. Molar ratio between lipid components 
was 26.5:20:52:1.5. For dialysis, three times volume of PBS was added 
to the LNPs solution. For ApoE association, mRNA-loaded LNPs 
were incubated with ApoE3 (0.1 g/ml) for 10 min at room tempera-
ture and treated to prepared HeLa cells at mRNA dose of 0.25 g/ml. 
Six hours later, cells were lysed with Bright-Glo reagents and rela-
tive luminescence was read on a Tecan plate reader. For inhibition 
of LDLR receptor, HeLa cells were treated with anti-LDLR antibody 
(5 g/ml) at 37°C for 1 hour and the medium was replaced with a 
serum-containing medium. mFLuc-loaded LNPs were treated to pre-
pared HeLa cells and incubated for 3 hours. After incubation, the 
medium was replaced and incubated for 24 hours in serum-containing 
media. Twenty-four hours later, cells were lysed with Bright-Glo reagents 
and luminescence intensity was read on a Tecan plate reader. Cell 
viability was measured using Pierce Coomassie Plus (Thermo Fisher 
Scientific). Luminescence level was normalized to cell viability.
In vitro evaluation of CD206-dependent uptake
HepG2 cells were prepared in a 96-well plate 16 hours before trans-
fection at 80% confluency. 246C10 were formulated into LNPs with 
mFLuc, together with DOPE, cholesterol, PEG-lipid, and mannose- 
PEG lipid by pipetting. mFLuc-loaded LNPs were treated to prepared 
HepG2 cells in the presence or absence of serum. After 3 hours, 
medium was replaced with serum-containing medium. Twenty-four 
hours later, cells were lysed with Bright-Glo reagents and relative 
luminescence was read on a Tecan plate reader. Cell viability was 
measured by Pierce Coomassie Plus (Thermo Fisher Scientific). 
Luminescence level was normalized to cell viability. For inhibition 
of mannose- or galactose-incorporated LNP uptake, HepG2 cells 
were treated with anti-CD206 antibody at 37°C for 3 hours and the 
medium was replaced with a serum-containing medium. mFLuc- 
loaded LNPs were treated to prepared HepG2 cells. Three hours later, 
the medium was replaced and incubated for 24 hours in serum- 
containing media.
In vivo evaluation of ionizable lipid candidates
Procedures for animal studies were approved by the Institutional 
Animal Care and Use Committee at the Ewha Womans University. 
Female C57BL/6 mice (7 to 10 weeks old) were purchased from 
ORIENT BIO. LNPs for in vivo imaging were formulated with 
mRNA encoding luciferase (mFLuc). Ionizable lipids:RNA weight 
ratio was 10:1, and molar ratio between lipids was 26.5:20:52:1.5 
(ionizable lipid, DOPE, cholesterol, and PEG-lipid). Formulated 
LNPs were administered intravenously to mice at a dose of mFLuc 
at 0.1 mg/kg. Three hours later, d-luciferin was injected intraperitoneally 
and incubated for 15 min. Luciferase expression of whole-body and 
ex vivo organ imaging was confirmed by an IVIS (PerkinElmer).
To confirm ApoE-dependent uptake of LNPs by the liver, 6-week-old 
male ApoE−/− mice were obtained from ORIENT BIO. mFLuc-LNPs 
were incubated with ApoE (0.1 mg/kg) overnight at 4°C and injected 
to mice. Three hours later, bioluminescence was compared with 
that of mFLuc-LNP–injected mice (without incubation of ApoE).
Evaluation of LNPs delivery in LSL (loxP-STOP-loxP)–
tdTomato mice
Procedures for animal studies were approved by the Institu-
tional Animal Care and Use Committee at the Yonsei University. 
LSL-tdTomato mice (007914) were purchased from the Jackson 
laboratory. To confirm liver cell type–dependent gene editing, LNPs 
were prepared with mCre. Eight-week-old mice were intravenously 
injected at a dose of 0.5 mg/kg. After 2 days, mice were anesthetized 
by isoflurane and the liver was perfused with 25 ml of 1× PBS. The 
liver was collected in a 50-ml conical tube and digested with Liberase 
(Sigma-Aldrich) at room temperature for 45 min. Digested cells were 
filtered through a 40-m mesh. Then, cells were stained with specific 
antibodies according to the manufacturer’s protocol. The antibodies 
used for specific liver cell type detection were APC (Allophycocyanin)–
labeled anti- CD31 (BioLegend), fluorescein isothiocyanate–labeled 
anti-CD45 (BioLegend), and PE/cy7-labeled anti-CD68 (BioLegend), 
and PE- labeled anti-CD47 (BioLegend) was used for tdTomato com-
pensation. Last, hepatocytes and nonparenchymal cells were analyzed 
by NovoCyte 2060R (ACEA). Representative flow cytometry gate 
strategy is shown in fig. S10.
For immunofluorescence, isolated livers were fixed with 4% 
paraformaldehyde. After embedding paraffin, embedded tissue was 
sectioned (5 m) using microtome. Then, the sections incubated in 
pH 6.0 buffer (Dako, S1699) for heat-induced epitope retrieval 
(HIER). After HIER, the sections were stained with 4,6-diamidino- 
2-phenylindole, –smooth muscle actin (Abcam, ab5694), Hnf4 
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(Hepatocyte nuclear factor 4 alpha) (R&D Systems, PP-H1415-00), 
and F4/80 (Abcam, ab6640). Fluorescence was detected by fluorescent 
microscopy (EVOS FL). tdTomato fluorescence–positive cells were 
digitally counted with a MetaMorph microscopy automation and 
image analysis software.
In vivo screening of FVII and FVIII activity
To study size-dependent LNP delivery to specific liver cells, we pre-
pared siRNA against FVII-loaded (gift from Alnylam) and FVIII- 
loaded (ON-TARGETPlus SMARTpool siRNA, purchased from 
Dharmacon) LNPs. LNPs were complexed together with siRNA and 
lipid components. Ionizable lipids:DSPC:cholesterol:PEG-lipid molar 
ratio was 42.5:13:42.5:3, and PEG-lipid mole percent was decreased 
to 1.5% by expending that of cholesterol. For exogenous ligand- 
dependent targeting study, mannose-PEG lipid was added in 0.5 to 
2.5 mole percent to formulation. siRNA-loaded LNPs were injected 
intravenously, and 2 days (siFVIII) or 3 days (siFVII) later, blood was 
collected via cheek bleeding. Blood was mixed with 0.1 M sodium 
citrate, and the plasma was separated from the cells. FVII or FVIII levels 
in blood were determined using the Coaset FVII or Coaset FVIII 
chromogenic assay (Chromogenix, MA) according to the manufacturer’s 
protocol with a standard curve obtained from PBS- injected mice.
Statistical analysis
All data are shown as means ± SD. The data were analyzed by one-
way analysis of variance (ANOVA) and two-way ANOVA. P value 
of <0.05 was considered significant.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/9/eabf4398/DC1
View/request a protocol for this paper from Bio-protocol.
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